Advertisement
Screener

Monopar Therapeutics Inc. (MNPR) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 55.00% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2021-05-13

  • Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 55.00%, a 35.29% decline year-over-year.
  • Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-03-31 was 85.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month
2021-03-3155.00%
10-Q · filed 2021-05-13
2020-03-3185.00%
10-Q · filed 2021-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Altimmune, Inc. (ALT)United States$0.593B-6.43
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Indaptus Therapeutics, Inc. (INDP)United States$0.537B